Dr. Noggle will reprogram these skin cells into the various cell types that make up the brain, employing the NYSCF Global Stem Cell Array, a breakthrough automated robotic technology that produces standardized stem cell lines. Results are specific to the patient's genetic makeup, allowing researchers to uncover Alzheimer's-related changes at an individual level and to track changes that might otherwise go undiscovered.
"Having all the cell types together in the same dish enables us to mimic as closely as possible the normal and the diseased adult human brain," said Dr. Gandy. "In these mixed cultures, we will study the roughly three-dozen genes that have been linked to AD to see if any are dysfunctional in such a way as to cause one or more known features of the disease."
To encourage international collaboration in Alzheimer's treatment, consortium researchers will create a stem cell bank that can be accessed globally to accelerate drug screening worldwide. This collaboration is an example of NYSCF's commitment to work with global collaborators to advance research.
"We can, for the first time, test drugs across a large, diverse population of Alzheimer's patients, using only their cells. This stem cell resource will embolden scientific investigations and accelerate bench to beside delivery of new treatments," said Dr. Noggle. "We're incredibly excited to be working with Dr. Gandy and fellow collaborators to find a cure for Alzheimer's disease."
|Contact: Mount Sinai Press Office|
The Mount Sinai Hospital / Mount Sinai School of Medicine